Protein farnesyltransferase (FTase) catalyses the attachment of a farnesyl lipid group to numerous essential signal transduction proteins, including members of the Ras superfamily1. The farnesylation of Ras oncoproteins, which are associated with 30% of human cancers, is essential for their transforming activity2. FTase inhibitors are currently in clinical trials for the treatment of cancer2,3,4. Here we present a complete series of structures representing the major steps along the reaction coordinate of this enzyme. From these observations can be deduced the determinants of substrate specificity and an unusual mechanism in which product release requires binding of substrate, analogous to classically processive enzymes. A structural model for the transition state consistent with previous mechanistic studies was also constructed. The processive nature of the reaction suggests the structural basis for the successive addition of two prenyl groups to Rab proteins by the homologous enzyme geranylgeranyltransferase type-II. Finally, known FTase inhibitors seem to differ in their mechanism of inhibiting the enzyme.
This is a preview of subscription content
Subscribe to Journal
Get full journal access for 1 year
only $3.90 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Casey, P. J. & Seabra, M. C. Protein prenyltransferases. J. Biol. Chem. 271, 5289–5292 (1996)
Adjei, A. A. Blocking oncogenic Ras signalling for cancer therapy. J. Natl Cancer Inst. 93, 1062–1074 (2001)
Johnston, S. R. D. Farnesyl transferase inhibitors: a novel targeted therapy for cancer. Lancet Oncol. 2, 18–26 (2001)
Karp, J. E. et al. Current status of clinical trials of farnesyltransferase inhibitors. Curr. Opin. Oncol. 13, 470–476 (2001)
Huang, C., Hightower, K. E. & Fierke, C. A. Mechanistic studies of rat protein farnesyltransferase indicate an associative transition state. Biochemistry 39, 2593–2602 (2000)
Park, H.-W., Boduluri, S. R., Moomaw, J. F., Casey, P. J. & Beese, L. S. Crystal structure of protein farnesyltransferase at 2.25 Å resolution. Science 275, 1800–1804 (1997)
Long, S., Casey, P. J. & Beese, L. S. Co-crystal structure of protein farnesyltransferase with a farnesyl diphosphate substrate. Biochemistry 37, 9612–9618 (1998)
Strickland, C. L. et al. Crystal structure of farnesyl protein transferase complexed with a CaaX peptide and farnesyl diphosphate analogue. Biochemistry 37, 16601–16611 (1998)
Long, S. B., Casey, P. J. & Beese, L. S. The basis for K-Ras4B binding specificity to protein farnesyltransferase revealed by 2 Å resolution ternary complex structures. Struct. Fold. Des. 8, 209–222 (2000)
Furfine, E. S., Leban, J. J., Landavazo, A., Moomaw, J. F. & Casey, P. J. Protein farnesyltransferase: Kinetics of farnesyl pyrophosphate binding and product release. Biochemistry 34, 6857–6862 (1995)
Dolence, J. M., Rozema, D. B. & Poulter, C. D. Yeast protein farnesyltransferase. Site-directed mutagenesis of conserved residues in the beta-subunit. Biochemistry 36, 9246–9252 (1997)
Kral, A. M. et al. Mutational analysis of conserved residues of the beta-subunit of human farnesyl:protein transferase. J. Biol. Chem. 272, 27319–27323 (1997)
Wu, Z. et al. Farnesyl protein transferase: identification of K164α and Y300β as catalytic residues by mutagenesis and kinetic studies. Biochemistry 38, 11239–11249 (1999)
Reiss, Y., Brown, M. S. & Goldstein, J. L. Divalent cation and prenyl pyrophosphate specificities of the protein farnesyltransferase from rat brain, a zinc metalloenzyme. J. Biol. Chem. 267, 6403–6408 (1992)
Mathis, J. R. & Poulter, C. D. Yeast protein farnesyltransferase: a pre-steady-state kinetic analysis. Biochemistry 36, 6367–6376 (1997)
Yokoyama, K., Zimmerman, K., Scholten, J. & Gelb, M. H. Differential prenyl pyrophosphate binding to mammalian protein geranylgeranyltransferase-I and protein farnesyltransferase and its consequence on the specificity of protein prenylation. J. Biol. Chem. 272, 3944–3952 (1997)
Tschantz, W. R., Furfine, E. S. & Casey, P. J. Substrate binding is required for release of product from mammalian protein farnesyltransferase. J. Biol. Chem. 272, 9989–9993 (1997)
Stradley, S. J., Rizo, J. & Gierasch, L. M. Conformation of a heptapeptide substrate bound to protein farnesyltransferase. Biochemistry 32, 12586–12590 (1993)
Koblan, K. S. et al. NMR studies of novel inhibitors bound to farnesyl-protein transferase. Prot. Sci. 4, 681–688 (1995)
Cate, J. H., Yusupov, M. M., Yusupova, G. Z., Earnest, T. N. & Noller, H. F. X-ray crystal structures of 70S ribosome functional complexes. Science 285, 2095–2104 (1999)
Farnsworth, C. C., Seabra, M. C., Ericsson, L. H., Gelb, M. H. & Glomset, J. A. Rab geranylgeranyl transferase catalyzes the geranylgeranylation of adjacent cysteines in the small GTPases Rab1A, Rab3A, and Rab5A. Proc. Natl Acad. Sci. USA 91, 11963–11967 (1994)
Novick, P. & Zerial, M. The diversity of Rab proteins in vesicle transport. Curr. Opin. Cell Biol. 9, 496–504 (1997)
Thoma, N. H., Niculae, A., Goody, R. S. & Alexandrov, K. Double prenylation by RabGGTase can proceed without dissociation of the mono-prenylated intermediate. J. Biol. Chem. 276, 48631–48636 (2001)
Zhang, H., Seabra, M. C. & Deisenhofer, J. Crystal structure of Rab geranylgeranyltransferase at 2.0 Å resolution. Struct. Fold. Des. 8, 241–251 (2000)
Desnoyers, L. & Seabra, M. C. Single prenyl-binding site on protein prenyl transferases. Proc. Natl Acad. Sci. USA 95, 12266–12270 (1998)
Thoma, N. H. et al. Allosteric regulation of substrate binding and product release in geranylgeranyltransferase type II. Biochemistry 40, 268–274 (2001)
Ashby, M. N. CaaX converting enzymes. Curr. Opin. Lipidol. 9, 99–102 (1998)
Long, S. B., Hancock, P. J., Kral, A. M., Hellinga, H. W. & Beese, L. S. The crystal structure of human protein farnesyltransferase reveals the basis for inhibition by CaaX tetrapeptides and their mimetics. Proc. Natl Acad. Sci. USA 98, 12948–12953 (2001)
Bell, I. M. G. et al. 3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency. J. Med. Chem. 45, 2388–2409 (2002)
Strickland, C. L. et al. Tricyclic farnesyl protein transferase inhibitors: crystallographic and calorimetric studies of structure-activity relationships. J. Med. Chem. 42, 2125–2135 (1999)
We thank H. W. Hellinga for extensive discussions and K. L. Terry for assistance with crystallization and data collection. The work was supported by National Institutes of Health grants to L.S.B. and P.J.C., and an American Heart Association predoctoral fellowship to S.B.L.
The authors declare that they have no competing financial interests.
About this article
Cite this article
Long, S., Casey, P. & Beese, L. Reaction path of protein farnesyltransferase at atomic resolution. Nature 419, 645–650 (2002). https://doi.org/10.1038/nature00986
Nature Communications (2019)
Nature Structural & Molecular Biology (2019)
Nature Reviews Molecular Cell Biology (2016)
Nature Communications (2016)